CLTX-305 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
235副甲状腺機能低下症1

235. 副甲状腺機能低下症


臨床試験数 : 88 薬物数 : 107 - (DrugBank : 24) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 7
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04465227
(ClinicalTrials.gov)
July 15, 20209/7/2020Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 in Autosomal Dominant Hypocalcemia Type 1 (ADH1)A Phase IIb, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX Hypocalcemia Type l (ADHl).HypoparathyroidismDrug: CLTX-305National Institute of Dental and Craniofacial Research (NIDCR)NULLNot yet recruiting16 YearsN/AAll20Phase 2United States